
Tango Therapeutics cuts nearly one-fifth of staff
Oncology drugmaker Tango Therapeutics has cut about 20% of its staff, following a year in which it twice trimmed its pipeline of experimental cancer drugs. The company “made the difficult decision” to reduce spending on preclinical research and lay off …